Nurix Therapeutics, Inc.
NRIX
$9.63
$0.101.05%
NASDAQ
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 138.75% | 38.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 138.75% | 38.91% | |||
| Cost of Revenue | 12.11% | 3.63% | |||
| Gross Profit | 33.53% | 5.06% | |||
| SG&A Expenses | 22.55% | 8.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.60% | 4.33% | |||
| Operating Income | 23.13% | 2.77% | |||
| Income Before Tax | 24.22% | 3.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.87% | 3.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.87% | 3.75% | |||
| EBIT | 23.13% | 2.77% | |||
| EBITDA | 23.85% | 4.56% | |||
| EPS Basic | 23.16% | 9.68% | |||
| Normalized Basic EPS | 24.51% | 9.67% | |||
| EPS Diluted | 23.16% | 9.68% | |||
| Normalized Diluted EPS | 24.51% | 9.67% | |||
| Average Basic Shares Outstanding | 0.38% | 6.57% | |||
| Average Diluted Shares Outstanding | 0.38% | 6.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||